Info Ior
Alendronate sodium
Reference(s):
WO 9 506 052 (Merck & Co.; USA-prior. 25.8.1993). WO 9 533 756 (Merck & Co.; appl. 2.6.1995; USA-prior. 6.6.1994). US 5 510 517 (Merck & Co.; 2.3.1995; USA-prior. 25.8.1993). DE 3 016 289 (Henkel KG; D-prior. 28.4.1980).
BE896 453 (1st. Gentili s. p. a.; appl. 14.4.1983; I-prior. 15.4.1982,16.2.1983). BE903 513 (1st. Gentili s. p. a.; appl. 25.10.1985; I-prior. 29.10.1984). EP494 844 (1st. Gentili s. p. a.; appl. 2.1.1992; I-prior. 8.1.1991). US 4 621 077 (1st. Gentili s. p. a.; 8.6.1984; I-prior. 15.4.1982). US 5 019 651 (Merck & Co.; 27.12.1991; USA-prior. 20.6.1990). US 4 922 007 (Merck & Co.; 1.5.1990; USA-prior. 9.6.1989).
alternative process for the production of alendronate: WO 9 834 940 (Apotcx Inc.; CA-prior. 11.2.1997).
Formulation(s): amp. 5 mg, 10 mg; tabl. 5 mg, 10 mg, 40 mg (as sodium salt)
54 A Alfacalcidol
Trade Name(s):
D: Fosamax (Merck Sharp & Dohme)
GB: Fosamax (Merck Sharp &
Dohme) I: Adronat (Neopharmed)
Alendros (Gentiii) Dronal (Sigmatau) Fosamax (Merck Sharp & Dohme)
Onclast (Banyu)
Teiroc (Teijin) USA: Fosamax (Merck Sharp & Dohme; 1993)
Alfacalcidol atc: aiicco3
(1 a-Hydroxycholecalciferol; 1 «-Hydroxy-vitamin D3) Use: calcium metabolism regulator, vitamin D-derivative rn: 41294-56-8 MF: c^h^o;, MW: 400.65 einecs: 255-297-1 LD50: 440 g/kg (M, p.o.);
340 g/kg (R, p.o.) cn: (la,3ß,5Z,7£)-9,10-secocholesta-5,7,10(19)-triene-l,3-diol
oxo-1,5.7-cholestatriene
3-OXO-1,4,6-cholestatriene oxo-1,5.7-cholestatriene
3-OXO-1,4,6-cholestatriene
- Alfacolcidol
Reference(s):
US 3 929 770 (Wisconsin Alumni Res.; 30.12. 1975; J-prior. 3.12.1973). alternative syntheses:
Holick, M.F. et al.: Science (Washington, D.C.) (SCIEAS) 180, 190 (1973).
Barton, D.H.R. et al.: J. Am. Chem. Soc. (JACSAT) 95, 2748 (1973)..
Fürst, A. et al.: Helv. Chim. Acta (HCACAV) 56, 1708 (1973).
US 3 966 777 (YedaRes. & Devel.; 29.6.1976; IL-prior. 22.10.1974).
DOS 2 259 661 (Wisconsin Alumni Res.; appl. 1.12.1972; USA-prior. 2.12.1971).
BE 877 356 (Wisconsin Alumni Res.; appl. 28.6.1979; USA-prior. 15.1.1979, 21.5.1979).
GB 1 553 321 (Merck & Co.; valid from 30.6.1977; USA-prior. 1.7.1976).
DOS 2 923 953 (Upjohn; appl. 13.6.1979; USA-prior. 19.6.1978).
total synthesis:
Harrison, R.G. et al.: Tetrahedron Lett. (TELEAY) 1973, 3649. synthesis of intermediates:
US 4046 760 (Merck & Co., 6.9.1977; prior. 1.7.1976).
pharmaceutical formulation:
US 4 164 569 (Chugai; 14.8.1979; J-prior. 8.4.1977).
use as anti-inflammatory:
Formulation(s): amp. 0.001 mg, 0.002 mg; cps. 0.001 mg, 0.0025 mg, 1 mg; inj. 2 |J.g/ml Trade Name(s):
D: Bondiol (Gry) One Alpha (Leo) Diseon (Smith Kline &
Eins Alpha (Leo) I: Dediol (Rhône-Poulenc French)
RN: 23930-37-2 MF: C23H3405 MW: 390.52 EINECS: 245-942-5 LD50: >30 mg/kg (rabbit, i.v.)
CN: (3a,5a)-21-(acetyloxy)-3-hydroxypregnane-l 1,20-dione alfadolone
RN: 14107-37-0 MF: C21H3204 MW: 348.48 EINECS: 237-961-2 LD,(): 59 mg/kg (M, i.v.)
Alfadolone acetate
(Alphadolone acetate)
ATC: N01A
Use: anesthetic (intravenous)
56 A Alfaxalone
Post a comment